疫苗铝佐剂与潜在健康影响的系统综述
该系统综述遵循PRISMA 2020指南,检索六大数据库及试验注册库至2025年11月27日,纳入59项人类研究评估铝佐剂疫苗的健康结局。随机对照试验和大型队列的高质量证据一致显示铝佐剂疫苗与严重或长期健康结局无关联,最常见反应为不常见、局部且自限的持续性结节或肉芽肿。
要点
- 随机对照试验和大型队列高质量证据显示铝佐剂疫苗与哮喘、自闭症谱系障碍等严重或长期结局无关联。
- 含铝佐剂疫苗后持续性结节或肉芽肿不常见(<1%),为局部自限性超敏反应,证据确定性中至低。
- 巨噬细胞肌筋膜炎研究样本小、方法学受限,未提供可信因果证据(确定性极低)。
核心结论
- 当前证据不支持铝佐剂疫苗与严重或长期健康结局之间存在因果关系。
- 记录最一致的反应为不常见、局部且自限的超敏反应性持续性结节或肉芽肿。
- 部分结局的方法学受限研究占主导,凸显需更高质量研究。
研究设计与样本
- 系统综述遵循PRISMA 2020指南,检索6个数据库及试验注册库,从建库至2023年3月3日,后更新至2025年11月27日。
- 纳入评估铝佐剂疫苗接种后健康结局的人类研究,包括随机对照试验、队列研究、病例系列和生态学研究。
- 共纳入59项研究:37项病例系列、11项随机对照试验、9项队列研究、2项生态学研究。
- 两名评价者筛选研究(2023-25更新有AI辅助)、提取数据并评估偏倚风险(RoB 2.0、ROBINS-I或病例系列适配工具)。
- 采用GRADE评级证据确定性;系统综述注册号PROSPERO CRD42023462831。
主要发现
- 随机对照试验和大型队列的高质量证据一致显示铝佐剂疫苗与哮喘、自闭症谱系障碍或其他慢性病等严重或长期健康结局无关联。
- 巨噬细胞肌筋膜炎相关研究通常样本小且方法学受限,未提供可信因果关联证据(确定性极低)。
- 含铝佐剂白喉-破伤风-百日咳疫苗后偶见局部持续性结节或肉芽肿,符合迟发型超敏反应(<1%,自限性;确定性中至低)。
- 对于常见不良事件(如头痛、肌痛),高确定性随机对照试验未发现含铝佐剂配方风险一致性增加;观察到的差异小且多为轻至中度。
- 证据以方法学受限研究为主,多数病例系列和生态学研究存在严重或极严重偏倚风险;结论主要基于较高质量随机对照试验和队列证据。
关键数值与推荐
- 纳入标准:评估铝佐剂疫苗接种后健康结局的人类研究,含随机对照试验、队列研究、病例系列和生态学研究。
- 排除标准:研究性疫苗、病例报告和综述文章。
- 含铝佐剂白喉-破伤风-百日咳疫苗后持续性结节或肉芽肿发生率<1%,自限性,证据确定性中至低。
- 巨噬细胞肌筋膜炎因果关联证据确定性极低。
- 常见不良事件(如头痛、肌痛)风险一致性增加未获高确定性随机对照试验支持。
临床怎么用
- 可依据当前高质量证据向公众和受种者说明铝佐剂疫苗与严重或长期健康结局无因果关联。
- 接种含铝佐剂疫苗后偶发持续性结节或肉芽肿多为局部自限性反应,可按迟发型超敏反应管理。
- 对巨噬细胞肌筋膜炎等罕见事件的相关主张应指出现有证据确定性极低、方法学受限。
- 临床决策和沟通可参考本综述结论,其与上市后监测发现广泛一致。
局限性
- 证据以方法学受限研究为主,多数病例系列和生态学研究存在严重或极严重偏倚风险。
- 巨噬细胞肌筋膜炎相关研究通常样本小且方法学受限。
- 部分结局缺乏高质量研究,需更高质量研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To systematically review and critically appraise human evidence on potential health effects of aluminium adjuvanted vaccines. DESIGN: Systematic review following PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines. DATA SOURCES: Six databases and trial registries were searched from inception to 3 March 2023 then updated to 27 November 2025. Reference lists of eligible studies were also screened. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Human studies assessing health outcomes after aluminium adjuvanted vaccination, including randomised controlled trials, cohort studies, case series, and ecological studies. Investigational vaccines, case reports, and review articles were excluded. DATA EXTRACTION AND SYNTHESIS: Two reviewers screened studies (with AI assistance for the 2023-25 update), extracted data, and assessed risk of bias (using RoB 2.0, ROBINS-I, or an adapted tool for case series). Certainty of evidence was rated using GRADE (Grading of Recommendations Assessment, Development, and Evaluation). RESULTS: The review included 59 studies (37 case series, 11 randomised controlled trials, nine cohort studies, two ecological studies). High quality evidence from randomised controlled trials and large cohorts consistently showed no association between aluminium adjuvanted vaccines and serious or long term health outcomes, such as asthma, autism spectrum disorders, or other chronic conditions. Studies on macrophagic myofasciitis were generally small and methodologically limited, and did not provide credible evidence of a causal association (very low certainty). Localised persistent nodules or granulomas were observed infrequently after diphtheria-tetanus-pertussis vaccines, consistent with delayed type hypersensitivity (<1%, self-limited; moderate to low certainty). For common adverse events (eg, headache, myalgia), high certainty randomised controlled trials found no consistent increase in risk with aluminium adjuvanted formulations. When differences were observed, they were small and predominantly mild to moderate in severity. Evidence was dominated by methodologically limited studies, with most case series and ecological studies at serious or critical risk of bias. Conclusions are primarily supported by higher quality randomised controlled trials and cohort evidence. CONCLUSIONS: Current evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were persistent nodules or granulomas that are uncommon, local, and self-limited hypersensitivity reactions. These findings are broadly consistent with post-licensure surveillance findings. The predominance of methodologically limited studies for some outcomes highlights the need for higher quality research. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023462831.
引用
- Doyon-Plourde P, Chong J, Abrams EM, et al. Aluminium adjuvants in vaccines and potential health effects: systematic review. BMJ. 2026. PMID: 42091164. doi:10.1136/bmj-2025-088921
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。